PCSK9 and hyperlipidemia: Recent PheWAS studies have focused on PCSK9, and all confirm the known association between PCSK9‐inhibitor lipid‐lowering medication and decreased risk of hypercholesterolaemia, hyperlipidaemia and cardiovascular disease.9, 39, 40